Please register for an event below.


Osteoporosis: Risk, Diagnosis, and Fracture Prevention
An On-demand CME/CE Webcast

OVERVIEW
Osteoporosis is a progressive skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue that is associated with significant fragility fractures and morbidity. By one estimate, 10 million people in the United States have been diagnosed with osteoporosis, and an additional 34 million with low bone mass are at an increased risk to develop the disease.

Diagnosis of osteoporosis is largely based on the measurement of bone mineral density (BMD). Testing for BMD and the use of T-scores permits the diagnosis to be made and treatment to be initiated in individuals who have not sustained a fragility fracture, but who may be at risk of future fracture. Nonetheless, it is now evident from the National Osteoporosis Risk Assessment study that one-half of osteoporotic fractures occur in women whose T-scores are above -2.5. These limitations have led to the development of the FRAXTM tool, which integrates other independent risk factors to provide an algorithm to assess fracture risk levels. Most of the available therapeutic agents for the prevention and treatment of osteoporosis are antiresorptive. However, all patients benefit from nonpharmacological lifestyle interventions, such as correcting calcium and vitamin D deficiency, exercising, smoking cessation, and moderating alcohol intake.

Using case vignettes, this activity will discuss the use of BMD testing and FRAXTM in the diagnosis of osteoporosis, identify treatment strategies for patients with acute fractures, discuss risk factors and prevention strategies for nonvertebral fractures, and outline appropriate and effective treatment options.

SPONSORSHIP AND SUPPORT
This meeting is sponsored by The Chatham Institute and supported through an educational grant from the Alliance for Better Bone Health (Proctor and Gamble Pharmaceuticals and sanofi-aventis U.S.).

LEARNING OBJECTIVES
At the end of this program, the participant should have improved his/her ability to:

TARGET AUDIENCE
This program is intended for clinicians specializing in primary care, endocrinology, rheumatology, and obstetrics/gynecology involved in the treatment of patients with osteoporosis.

VERIFICATION OF PARTICIPATION
At the completion of the Webcast, you will be directed to www.ce-university.org to complete a posttest and evaluation form, and to verify and submit your contact information by email. Once complete, you will be able to print your CME/CE certificate.

FACULTY
PLANNING COMMITTEE

John P. Bilezikian, MD
Dorothy L. and Daniel H. Silberberg Professor of Medicine
Professor of Pharmacology
Department of Medicine
College of Physicians and Surgeons, Columbia University
New York, NY

Richard S. Pope, MPAS, PA-C
President, Society of Physician Assistants in Rheumatology;B Adjunct Clinical Professor
Quinnipiac University
Hamden, CT

Susan J. Wysocki, RN, WHNP-BC, FAANP
President and CEO
National Association of Nurse Practitioners in Women's Health
Washington, DC

PRESENTER

Kenneth G. Saag, MD, MSc
Professor of Medicine and Epidemiology
Director, Center for Education and Research on Therapeutics of Musculoskeletal Disorders
Division of Clinical Immunology and Rheumatology
University of Alabama
Birmingham, AL

ACCREDITATION AND DESIGNATION
The Chatham Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Chatham Institute designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Chatham Institute LLC is an approved provider of continuing nursing education by the New Jersey State Nurses Association (NJSNA), an accredited approver by the American Nurses Credentialing Center's (ANCC's) Commission on Accreditation, provider number P175-11/2006-2009.

The Chatham Institute LLC is approved by the California Board of Registered Nursing (CBRN), provider number CEP 12433.

This activity is approved for 1.0 contact hour.

Disclaimer: Accreditation refers to educational content only and does not imply endorsement of products by NJSNA, ANCC, CBRN, or The Chatham Institute LLC.

This program is pending approval from the American Association of Nurse Practitioners. This program is not yet approved for CME credit.

The American Academy of Physician Assistants accepts certificates of participation for educational activities certified for Category 1 credit from the AOACCME, prescribed credit from the American Academy of Family Physicians, and AMA PRA Category 1 CreditTM from organizations accredited by the ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.0 hours of Category I credit for completing this program.

DISCLOSURE
It is the policy of The Chatham Institute to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. All faculty who affect the content of medical education activities sponsored by The Chatham Institute are required to disclose to the audience any real or apparent conflict of interest related to the activity. The activity faculty are further required to disclose discussion of off-label uses in their presentations. Faculty not complying with the disclosure policy are not permitted to participate in the educational activity.

Program faculty and planners have disclosed the financial relationships with commercial interests below. All program content has been peer reviewed for balance and any potential bias. The conflict of interest resolution process aims to ensure that financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of continuing medical education activities for the profession.

John P. Bilezikian, MD
Advisory Boards: Eli Lilly and Company, Novartis Pharmaceuticals Corporation, sanofi-aventis U.S. LLC
Consultant: Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, sanofi-aventis U.S. LLC
Grant Research: Novartis Pharmaceuticals Corporation, sanofi-aventis U.S. LLC

Richard S. Pope, MPAS, PA-C
Speaker Bureaus: Amgen Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc, Wyeth Pharmaceuticals
Consultant: Abbott Laboratories

Susan J. Wysocki, RN, WHNP-BC, FAANP
Speaker Bureaus: Barr Pharmaceuticals, Inc., Bayer, Ther-Rx Corporation, Wyeth Pharmaceuticals
Consultant: Eli Lilly and Company
Advisory Boards: Barr Pharmaceuticals, Inc., Bayer, Eli Lilly and Company, Merck & Co., Inc., Ortho-McNeil, Inc., and Wyeth Pharmaceuticals

Kenneth G. Saag, MD, MSc
Speaker Bureaus: Merck & Co., Inc., Novartis Pharmaceuticals Corporation
Advisory Boards: Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation
Consultant: Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals
Research Grants: Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation

Bagirathy Ravishankar, PhD
Scientific Director, The Chatham Institute
No real or apparent relationships to disclose

Independent peer reviewers have nothing to disclose.